Chronic hepatitis C virus (HCV) infection is well-recognized as a common blood borne infection with global public health impact, affecting 3 to 5 million persons in the U.S. and over 170 million persons worldwide. Chronic HCV infection is associated with significant morbidity and mortality due to complications of liver cirrhosis and hepatocellular carcinoma (HCC). Current therapies with all-oral directly acting antiviral agents (DAAs) are associated with high rates of sustained virologic response (SVR), generally exceeding 90%. SVR is associated with a reduced risk of liver cirrhosis, hepatic decompensation, need for liver transplantation, and both liver-related and all-cause mortality. However, a subset of patients who achieve SVR will remain at long-term risk for progression to cirrhosis, liver failure, HCC, and liver-related mortality. Limited evidence is available to guide clinicians on which post-SVR patients should be monitored versus discharged, how to monitor and with which tests, how frequently should monitoring occur, and for how long. In this clinical practice update, available evidence and expert opinion are used to generate best practice recommendations on the care of patients with chronic HCV who have achieved SVR.
2017年AGA指南更新:丙型肝炎治疗血清学应答患者的临床管理
发布日期:2017-03-23
英文标题:AGA Institute Clinical Practice Update: Care of Patients Who Have Achieved a Sustained Virologic Response (SVR) Following Antiviral Therapy for Chronic Hepatitis C Infection
来源:Gastroenterology, 2017
阅读次数:1318
相关指南
- 2017年丙型肝炎治疗建议
- 2017年AGA指南:对经抗病毒治疗获持续病毒学应答的慢性丙型肝炎患者的管理
- 2016年澳大拉西亚肝病学会共识:丙型肝炎患者应用直接抗病毒药物依从性管理
- 2017年WGO全球指南:丙型肝炎的诊断,管理和预防
- 2017年CTFPHC建议:成人丙肝筛查
- 2017年AGA指南更新:丙型肝炎治疗血清学应答患者的临床管理
- 2017年多学科专家共识:HCV相关性肝外疾病的国际治疗指南
- 2016年AHA共识指南:支持丙型肝炎患者应用直接抗病毒药物
- 《2016年欧洲肝病学会丙型肝炎治疗指南》解读及分析
- 《多学科专家声明:HCV相关性肝外表现患者诊断指南》摘译
- 2016年MASAC建议:血友病和其他出血性疾病患者丙型肝炎的治疗(#247)